Novelmed Takes ‘Complementary’ Approach to MAbs
After a decade of work in the lab, Novelmed Therapeutics Inc. has its sights set on moving its lead compound into human studies in paroxysmal nocturnal hemoglobinuria (PNH) and two models of age-related macular degeneration (AMD).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter